Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results
Author
Abstract
Suggested Citation
DOI: 10.1007/s40258-020-00600-w
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Scott A. McDonald & Amirah Azzeri & Fatiha Hana Shabaruddin & Maznah Dahlui & Soek S. Tan & Adeeba Kamarulzaman & Rosmawati Mohamed, 2018. "Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018–2040," Applied Health Economics and Health Policy, Springer, vol. 16(6), pages 847-857, December.
- Matteo Ruggeri & Federica Romano & Michele Basile & Silvia Coretti & Francesca Romana Rolli & Carlo Drago & Americo Cicchetti, 2018. "Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy," Applied Health Economics and Health Policy, Springer, vol. 16(5), pages 711-722, October.
- Daniëla K van Santen & Anneke S de Vos & Amy Matser & Sophie B Willemse & Karen Lindenburg & Mirjam E E Kretzschmar & Maria Prins & G Ardine de Wit, 2016. "Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands," PLOS ONE, Public Library of Science, vol. 11(10), pages 1-18, October.
- Andrew J. Leidner & Harrell W. Chesson & Philip R. Spradling & Scott D. Holmberg, 2017. "Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease," Applied Health Economics and Health Policy, Springer, vol. 15(1), pages 65-74, February.
- Miriam Luhnen & Siw Waffenschmidt & Andreas Gerber-Grote & Gloria Hanke, 2016. "Health Economic Evaluations of Sofosbuvir for Treatment of Chronic Hepatitis C: a Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 14(5), pages 527-543, October.
- Elamin Elbasha & Jagpreet Chhatwal & Shannon Ferrante & Antoine El Khoury & Pedro Laires, 2013. "Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal," Applied Health Economics and Health Policy, Springer, vol. 11(1), pages 65-78, February.
- Paul Kind & Geoffrey Hardman & Susan Macran, 1999. "UK population norms for EQ-5D," Working Papers 172chedp, Centre for Health Economics, University of York.
- Barbara de Graaff & Kwang Chien Yee & Philip Clarke & Andrew Palmer, 2018. "Uptake of and Expenditure on Direct-Acting Antiviral Agents for Hepatitis C Treatment in Australia," Applied Health Economics and Health Policy, Springer, vol. 16(4), pages 495-502, August.
Citations
Blog mentions
As found by EconAcademics.org, the blog aggregator for Economics research:- Chris Sampson’s journal round-up for 1st February 2021
by Chris Sampson in The Academic Health Economists' Blog on 2021-02-01 12:00:03
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Bishal Mohindru & David Turner & Tracey Sach & Diana Bilton & Siobhan Carr & Olga Archangelidi & Arjun Bhadhuri & Jennifer A. Whitty, 2020. "Health State Utility Data in Cystic Fibrosis: A Systematic Review," PharmacoEconomics - Open, Springer, vol. 4(1), pages 13-25, March.
- Andrea Marcellusi & Raffaella Viti & Loreta A. Kondili & Stefano Rosato & Stefano Vella & Francesco Saverio Mennini, 2019. "Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data," PharmacoEconomics, Springer, vol. 37(2), pages 255-266, February.
- Dina Jankovic & Pedro Saramago Goncalves & Lina Gega & David Marshall & Kath Wright & Meena Hafidh & Rachel Churchill & Laura Bojke, 2022. "Cost Effectiveness of Digital Interventions for Generalised Anxiety Disorder: A Model-Based Analysis," PharmacoEconomics - Open, Springer, vol. 6(3), pages 377-388, May.
- Billingsley Kaambwa & Julie Ratcliffe, 2018. "Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People’s Quality of Life Brief Questionnaire (OPQoL-Brief) Scores," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 11(1), pages 39-54, February.
- Carsten Hirt & Sergio Iannazzo & Silvia Chiroli & Lisa J. McGarry & Philipp Coutre & Leif Stenke & Torsten Dahlén & Jeffrey H. Lipton, 2019. "Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leuk," Applied Health Economics and Health Policy, Springer, vol. 17(4), pages 555-567, August.
- Billingsley Kaambwa & Gang Chen & Julie Ratcliffe & Angelo Iezzi & Aimee Maxwell & Jeff Richardson, 2017. "Mapping Between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and Five Multi-Attribute Utility Instruments (MAUIs)," PharmacoEconomics, Springer, vol. 35(1), pages 111-124, January.
- Miqdad Asaria & Susan Griffin & Richard Cookson, 2016. "Distributional Cost-Effectiveness Analysis," Medical Decision Making, , vol. 36(1), pages 8-19, January.
- Donna Rowen & John Brazier & Clara Mukuria & Anju Keetharuth & Arne Risa Hole & Aki Tsuchiya & Sophie Whyte & Phil Shackley, 2016. "Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life," Medical Decision Making, , vol. 36(2), pages 210-222, February.
- Abdullah Pandor & Matt Stevenson & John Stevens & Marrissa Martyn-St James & Jean Hamilton & Jenny Byrne & Claudius Rudin & Andrew Rawdin & Ruth Wong, 2018. "Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 36(8), pages 903-915, August.
- Yin Liu & Hui Zhang & Lei Zhang & Xia Zou & Li Ling, 2020. "Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China," IJERPH, MDPI, vol. 17(3), pages 1-13, January.
- Stefano Capri, 2013. "The economics of orphan drugs: the case of osteosarcoma treatment," LIUC Papers in Economics 265, Cattaneo University (LIUC).
- Nádia Simões & Nuno Crespo & Sandrina B. Moreira & Celeste A. Varum, 2016.
"Measurement and determinants of health poverty and richness: evidence from Portugal,"
Empirical Economics, Springer, vol. 50(4), pages 1331-1358, June.
- Nádia Simões & Nuno Crespo & Sandrina B. Moreira & Celeste A. Varum, 2013. "Measurement and Determinants of Health Poverty and Richness – Evidence from Portugal," Working Papers Series 2 13-08, ISCTE-IUL, Business Research Unit (BRU-IUL).
- Miqdad Asaria & Susan Griffin & Richard Cookson, 2013.
"Distributional cost-effectiveness analysis: a tutorial,"
Working Papers
092cherp, Centre for Health Economics, University of York.
- Asaria, Miqdad & Griffin, Susan & Cookson, Richard, 2016. "Distributional cost-effectiveness analysis: a tutorial," LSE Research Online Documents on Economics 101271, London School of Economics and Political Science, LSE Library.
- Andrea Marcellusi & Francesco Saverio Mennini & Massimo Andreoni & Loreta A. Kondili, 2024. "Screening strategy to advance HCV elimination in Italy: a cost-consequence analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(7), pages 1261-1273, September.
- Muhammad Radzi Abu Hassan & Huan-Keat Chan, 2020. "Comment on: “Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection Under Different Treatment Policies in Malaysia, 2018–2040”," Applied Health Economics and Health Policy, Springer, vol. 18(1), pages 139-140, February.
- Andrea Manca & Nigel Rice & Mark J. Sculpher & Andrew H. Briggs, 2005. "Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 471-485, May.
- Laura Bojke & Andrea Manca & Miqdad Asaria & Ronan Mahon & Shijie Ren & Stephen Palmer, 2017. "How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(8), pages 767-776, August.
- Amy Dymond & Will Green & Mary Edwards & Maria Angeles Lopez Pont & Girish Gupta, 2023. "Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland," PharmacoEconomics - Open, Springer, vol. 7(3), pages 443-454, May.
- Franck Maunoury & Aurore Clément & Chizoba Nwankwo & Laurie Levy-Bachelot & Armand Abergel & Vincent Di Martino & Eric Thervet & Isabelle Durand-Zaleski, 2018. "Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France," PLOS ONE, Public Library of Science, vol. 13(3), pages 1-20, March.
- Jagpreet Chhatwal & Tianhua He & Maria A. Lopez-Olivo, 2016. "Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals," PharmacoEconomics, Springer, vol. 34(6), pages 551-567, June.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:19:y:2021:i:1:d:10.1007_s40258-020-00600-w. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.